A rather tragic irony that an Australian company with a likely treatment for C-19 ARDS saw its trial mishandled by the NIH is the US, when such a treatment, coupled with higher vaccine roll-outs might are clearly the answer to Australian's new predicament - that we are essentially isolated by our own success. Some 55% of the US have had their first vaccination. Over 10% of the population have had COVID-19. They are approching herd immunity and clearly moving on with life with less and less heed paid to COIVD-19.
Governor Cuomo describes New York as "thriving not surviving".
Countries like SIngapore with success similar to Australia are beginning to accpet they must live with some degree of COVID-19 in the community. How easier it would be for Australia to adopt a similar attitude if we had higher vaccination rates and a safety net for the critically ill like Remestemcel-L.
$90 a share on COVID ARDS Authorization ?, page-68
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |